Lupin, Zydus ink licensing pact

New Delhi: Pharma majors Lupin Ltd and Zydus Lifesciences Ltd on Friday said they have entered into a licensing and supply agreement to co-market Saroglitazar Mg for the treatment of non-alcoholic fatty liver disease and nonalcoholic steato hepatitis in India. Under the agreement, Lupin will have semi-exclusive rights to co-market the product in India under the brand name LINVAS. Zydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them, the two companies said in a joint statement.